Lufepirsen

N/A

Report date: 2024/08/02 20:01:06
NME

Base Information

Drug NameLufepirsen
Drug Alias NameNexagonCODA-001
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionGap junction alpha-1 protein inhibitors
TargetsGap junction alpha-1 protein
Therapy Area/IndicationsPersistent corneal epithelial defectWounds and InjuriesVaricose Ulcer +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNew ZealandSouth Africa +[7] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of California
China Registration ClassN/A

Develop Information

Active CompaniesGlaukos Corp
Inactive CompaniesUniversity Of California San FranciscoOcunexus Therapeutics Inc
Active IndicationsPersistent corneal epithelial defect
Inactive IndicationsWounds and InjuriesVaricose UlcerDiabetic Foot +[4] 

Other Information

ATC CodeN/A
Related LinksN/A